[Brimonidine intoxication in paediatrics. A presentation as intracranial hypertension syndrome]. / Intoxicación por brimonidina en pediatría. Presentación como síndrome de hipertensión intracraneal.

BACKGROUND: Brimonidine is an extremely lipophilic drug which is absorbed very well through the cornea and thus crosses the blood-brain barrier. This is very important for any potential toxic effects on the CNS. OBJECTIVES: To show the adverse effects of brimonidine and advise the need for caution in its use in the paediatric population. CONCLUSIONS: Brimonidine is prohibited from use in toddlers and infants. Its adverse effects can be severe or lethal. It should be suspected in treated patients with compatible symptoms in whom organic disease has been ruled out. We must stop the use of brimonidine and adopt support measures.

Intoxicación por brimonidina en pediatría. Presentación como síndrome de hipertensión intracraneal / Brimonidine intoxication in paediatrics. A presentation as intracranial hypertension syndrome

Antecedentes: La brimonidina es un fármaco muy lipofílico absorbido muy bien por vía transcorneal, que atraviesa la barrera hematoencefálica, con el potencial efecto tóxico para el sistema nervioso central que esto supone. Objetivos: Dar a conocer los efectos secundarios de la brimonidina tópica y remarcar la necesidad de precaución con fármacos tópicos en pediatría. Conclusiones: La brimonidina se desaconseja en niños pequeños y lactantes. Sus efectos secundarios sistémicos pueden ser graves o incluso letales. Debemos sospecharlo en pacientes tratados con síntomas compatibles en los que se descarta patología orgánica. Debemos actuar suspendiendo el fármaco y adoptando las medidas de soporte necesarias

Background: Brimonidine is an extremely lipophilic drug which is absorbed very well through the cornea and thus crosses the blood-brain barrier. This is very important for any potential toxic effects on the CNS. Objectives: To show the adverse effects of brimonidine and advise the need for caution in its use in the paediatric population. Conclusions: Brimonidine is prohibited from use in toddlers and infants. Its adverse effects can be severe or lethal. It should be suspected in treated patients with compatible symptoms in whom organic disease has been ruled out. We must stop the use of brimonidine and adopt support measures